Introduction

Breast cancer is one of the most prevalent cancers affecting women globally, with more than 2.3 million new diagnoses annually. In India, breast cancer represents the second leading cause of cancer deaths in women. For patients diagnosed with advanced or metastatic breast cancer, access to appropriate treatment options can significantly impact survival and quality of life.

How Does NPP Work?

Understanding Breast Cancer Classification

Modern breast cancer diagnosis involves more than confirming the disease is present. Doctors determine:

• Type of cancer: Invasive ductal carcinoma, invasive lobular carcinoma, or other subtypes
• Stage: How far the cancer has spread (localized, regional, or metastatic)
• Molecular characteristics: Testing for hormone receptors (estrogen and progesterone), HER2 status, and other biomarkers
• Overall health status:Ability to tolerate systemic treatment

This comprehensive assessment helps doctors recommend personalized treatment approaches.

Eligibility for NPP Access

To qualify for NPP, breast cancer patients typically must meet these criteria:

• Advanced or metastatic disease requiring urgent systemic intervention
• Exhaustion of suitable Indian-approved alternatives or inadequate response to standard treatments
• Medical evidence supporting potential benefit from the requested medication and it is approved in any other country especially USFDA or EMA
• Clear clinical justification by their treating physician
• Informed consent after understanding potential risks and benefits

Available Breast Cancer Treatment Options

Several systemic therapy approaches are used to treat advanced breast cancer:

Targeted Therapies for HER2-Positive Disease

For patients whose cancer shows high HER2 protein expression, HER2-directed therapies have revolutionized treatment outcomes:

• Tukysa (tucatinib) – for advanced HER2-positive disease
• Nerlynx (neratinib) – as extended therapy for HER2-positive breast cancer
• Lapatinib (available internationally) – a HER2-targeted kinase inhibitor

PARP Inhibitors

These medications are used for patients with specific genetic features, particularly BRCA mutations:

• Talzenna (talazoparib) – for gBRCA-positive, HER2-negative metastatic disease

Hormone Receptor-Positive Disease Treatments

For patients with hormone receptor-positive breast cancer:

• Orserdu (elacestrant) – an estrogen receptor degrader for hormone receptor-positive disease
• Truqap (capivasertib) – a PI3K pathway inhibitor for advanced disease
• Other hormone therapies and CDK4/6 inhibitors available internationally

Antibody-Drug Conjugates (ADCs)

These novel targeted agents combine antibodies with chemotherapy:

• Datroway (datopotamab deruxtecan-dlnk) – for advanced hormone receptor-positive disease

Immunotherapy Options

Checkpoint inhibitors are available for specific breast cancer subtypes, particularly triple-negative breast cancer, enhancing the body’s immune response against cancer cells.

The Role of Advocates Like MitoGENE

Organizations like MitoGENE facilitate the NPP process by:

• Educating patients and physicians about NPP and eligibility
• Facilitating patients to get 12 B import permit for personal use from CDSC
• Connecting patients with legitimate international medicine sources
• Ensuring regulatory compliance
• Providing documentation support for NPP applications
• Coordinating logistics for legal importation and delivery

By working with MitoGENE, patients access expertise and connections necessary to navigate NPP successfully.

“Plz Note: All clinical decisions—including whether a therapy is suitable—are made solely by the treating physician and MitoGENE does not influence prescribing decisions or the medical judgment of physicians”